Posters

4 years follow-up of dexamethasone intravitreal implant (Ozurdex®) in macular oedema (MO) due to retinal vein occlusions (RVO)

Poster Details

First Author: L.Makris UK

Co Author(s):    M. Loufti   A. Kamal                          

Abstract Details



Purpose:

A long term evaluation (follow up of 4 years period) of the efficacy and safety of intravitreal Ozurdex® implant in patient with MO secondary to either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in a clinic practice setting at a tertiary referral centre.

Setting:

University of Aintree (UHA) – Retinal department in a tertiary referral centre in Liverpool UK.

Methods:

Retrospective analysis of the data regarding patients with MO due to RVO treated with intravitreal Ozurdex® implant. Data was extrapolated from medical records and Medisoft® software. Clinical details recorded before the implant with documentation of fluorescein angiography (FFA) and spectral domain optical coherence tomography (SD-OCT) at each visit following the procedure include Log-MAR best correct visual acuity (BCVA), Intraocular pressure (IOP), cataract progression requiring surgery, SD-OCT and any complications. Criteria for retreatment was decreasing of BCVA and/or increasing MO based on SD-OCT. Were included 3 groups according to the BCVA outcome compared to baseline, group 1 were BCVA improved more or equal 2 Log-MAR lines, group 2 were BCVA not improved or worsen more than 1 log-MAR line and the group 3 were the BCVA worsen more or equal 2 log-MAR lines.

Results:

Our study cohort included 87 patients (BRVO: 57 patients, M:F=30:27 & CRVO: 30 patients, M:F=17:13). After 4 years follow up, the BCVA improved by ≥ 2 log-MAR lines in 35% of the BRVO group and 34.3% of the CRVO group, remained stable in 55% of the BRVO group and 40.6% of the CRVO group and declined by ≥ 2 LogMAR lines in 10% of the BRVO group and 25% of the CRVO group. Mean CMT decreased by 142µm in the BRVO group and by 307 µm in the CRVO group. The mean number of Ozurdex® implants required over the follow up period was 4 for both BRVO and CRVO groups. No per-operative complications were observed, 1 eye in both BRVO and CRVO groups developed neovascular glaucoma and 1 eye in the BRVO group developed endophthalmitis. 7 eyes in both BRVO and CRVO groups needed to use anti-glaucoma treatment and finally 33 and 23 eyes in the BRVO and CRVO groups respectively met the criteria of cataract surgical extraction.

Conclusions:

We report a long term follow up study of patients with venous occlusion treated with Ozurdex®. Our results indicate that it has favourable long-term safety profile, and may have a beneficial effect on the visual prognosis in RVO. The number of implants to treat decreased dramatically after the second year. In the paper we will discuss the differences of 2 and 4 year follows up with its benefits and perils.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy